Estudo antinociceptivo do deflazacort

AUTOR(ES)
DATA DE PUBLICAÇÃO

1996

RESUMO

The aim of this work is to stablish parameters for experimental assay to deflazacort, a glucocorticoid wich have few side effects on bone and glycemia. Two nociceptives and one of PMN accmnulation experimental models were done in order to evaluate the antinociceptive and antiinflammatory effects of deflazacort, when compared with dexamethasone and indometacin. SWISS male mice were treated with crescent doses of deflazacort (Calcort@, 0.075mg!kg to 2.4mg!kg), or dexamethasone (Decadron@, 1.0 to 4.0mg!kg), or saline 0.9% or indometacin 2.0mg!kg, 60 minutes before the nocive challenge. Acetic ~id writhing test showed that slow doses of deflazacort inhibit the acetic acidinduced stretching and writhing movements. lu fact, deflazacort were more potent that dexamethasone in this test (saline: 32.1 :t 0.96 movements in 15 ,minutes; deflazacort O, 15mg!kg: 18.8 :t 2.86 moviments; dexamethasone 2.0mg!kg: 22.2 :t 3.53 movements; indometacin 2.0mg!kg: 1~3.3 :t 3.32 movements, p<0.05). Deflazacort also were more potent in inhibit the late phase ofFormalin test (saline: 246.5 :!: 18.90 s; deflazacort 1.2mg!kg: 120.1 :!: 21.95 s; dexamethasone 2.0mg!kg: 134.9 :!: 39.38 s; indometacÍn 2.0mg!kg: 153.0 :!: 19.21 s, p<0.05). lu the model of leukocyte PMN migration, treatment with deflazacort, doses equal to or higher than 0.3mg!kg inhibited the PMN accumulation, while dexamethasone showed the same effect with doses equal to or higher than 3.0mg!kg (saline: 0.59 :t 0.06 xl06 PMN/mL; detlazacort O.3mg!kg: 0.31 :t 0.04 xl06 PMN/mL; dexamethasone 3.0mg!kg: 0.21 :!: 0.04 xl06 PMN/mL, p<0.05). These results point to a potent antinociceptive effect of detlazacort, when compared to dexamethasone, in the tested experimental models

ASSUNTO(S)

analgesia agentes antiinflamatorios corticosteroides inflamação

ACESSO AO ARTIGO

Documentos Relacionados